This content has not yet been reviewed and may contain errors.

cancer screening — Canadian guidelines

in review 4 min read Updated 2026-07-30
oncology screening prevention public-health Canadian-guidelines
Contents
cancer screening — Canadian guidelines

Summary of Canadian average-risk and increased-risk cancer screening recommendations. Key principle: screen only when evidence supports net benefit in the target population. Know which cancers are NOT routinely screened.

average-risk screening

CancerWhoTestInterval
breastwomen 50–74mammographyevery 2 years (most provincial programmes use biennial)
women 40–49shared decision-making based on individual values—
lungadults 55–74, ≥30 pack-year history, current smoker or quit ≤15 years agolow-dose CT (LDCT)annually × 3 consecutive years
colorectaladults 50–74 (average risk)FIT every 2 years (gFOBT acceptable alternative) OR flexible sigmoidoscopy every 10 yearssee interval
cervicalindividuals with a cervix, age 25–69Pap smear every 3 yearsevery 3 years; adequate screening = ≥3 consecutive negatives in preceding 10 years before stopping
HCCcirrhosis (Child-Pugh A/B)abdominal ultrasound ± AFPevery 6 months
Child-Pugh C cirrhosisscreen only if transplant candidate—
non-cirrhotic chronic HBV carriers — men from endemic regions ≥40, women from endemic regions ≥50, persons from Africa ≥20, or any age with family history of HCCabdominal ultrasound ± AFPevery 6 months
cervical screening — HPV testing transition

CTFPHC recommends cytology (Pap) every 3 years. Several provinces (BC, Ontario, others) are transitioning to primary HPV testing as a replacement — this is a provincial implementation change, not yet a CTFPHC guideline recommendation.

lung screening — weak recommendation

The CTFPHC lung screening guideline (2016) is a weak recommendation and has not been updated. Other jurisdictions (USPSTF 2021, NCCN) have broadened criteria to age 50+, ≥20 pack-years, and ongoing annual screening without a 3-year cap. Ontario’s lung screening pilot uses the PLCOm2012 risk model rather than simple age/pack-year criteria.

colonoscopy is not average-risk screening

Do not use screening colonoscopy routinely for average-risk individuals in Canada. FIT (or gFOBT) or flexible sigmoidoscopy is first-line. Colonoscopy is reserved for increased-risk populations or positive FIT follow-up.

increased-risk screening

CancerWhoTestInterval
colorectal≥1 first-degree relative with CRC or advanced adenomascreening colonoscopyevery 5–10 years, starting age 40 or 10 years before index case (whichever earlier)
attribution

Increased-risk CRC screening recommendations come from CAG/provincial guidance, not the CTFPHC (which addresses average risk only).

cancers NOT routinely screened (average risk)

PESTO mnemonic

Prostate — Esophagus — Skin/melanoma — Testes — Ovaries

why these are not screened

  • lack of evidence that screening reduces mortality in average-risk populations
  • screening tests have poor specificity → high false-positive rates → unnecessary biopsies, overdiagnosis, and overtreatment
  • many detected cancers are indolent and would never cause clinical harm (e.g. low-grade prostate cancer)

PSA screening — the controversy

  • CTFPHC recommends against routine PSA screening in average-risk men (any age)
  • rationale: PSA-based screening leads to overdiagnosis (~50% of screen-detected prostate cancers are indolent), unnecessary biopsies (infection, bleeding), and overtreatment (incontinence, erectile dysfunction) — with modest absolute mortality reduction
  • however: some patients and clinicians favour informed/shared decision-making, particularly in men aged 55–69 with ≥10-year life expectancy
  • if a patient requests PSA testing, the discussion should cover: the probability of a false positive, the risk of detecting indolent disease, the harms of prostate biopsy, and the modest mortality benefit
  • this is a values-based decision, not a knowledge deficit — the same evidence supports different choices for different patients

primary cancer prevention

tobacco cessation

  • brief health-worker counselling (30 seconds to 3 minutes) recommended for all tobacco users
  • pharmacotherapy:
    • varenicline — highest quit rates
    • bupropion — helpful if co-morbid depression; avoid in seizure disorders and eating disorders
    • NRT combination (patch + short-acting) — superior to monotherapy
  • SSRIs are not effective for smoking cessation

HPV vaccination

  • primary prevention for cervical, oropharyngeal, anal, and other HPV-related cancers
  • publicly funded school-based programmes across Canadian provinces (age varies by province, typically grade 4–7)
  • catch-up vaccination recommended for individuals up to age 26 (some guidelines extend to 45 for shared decision-making)

alcohol

  • risk of multiple malignancies (breast, colon, oropharyngeal, oesophageal, liver) increases even at low consumption levels
  • Canada’s Guidance on Alcohol and Health (2023): 3–6 standard drinks/week = moderate risk; no safe threshold established for cancer risk

Key references

+10 more sources